Lilly licenses anti-inflammatory from Incyte in deal worth up to $755 million
This article was originally published in Scrip
Lilly has licensed from Incyte worldwide rights to an oral JAK1/JAK2 inhibitor in a Phase II dose-ranging study for rheumatoid arthritis. Under the development and commercialisation pact, Lilly also has rights to certain follow-on compounds.
You may also be interested in...
During a mixed review by the US FDA's Arthritis Advisory Committee, panelists suggested that risks potentially associated with Lilly/Incyte's JAK inhibitor would be acceptable for a more limited patient population.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.